A small Seattle biotech wants to take on GlaxoSmithKline's emerging Shingrix blockbuster. RA Capital is on board
GlaxoSmithKline’s Shingrix has quickly become one of the company’s best-selling products since first winning FDA approval in 2017. But a new biotech believes it can do better — and RA Capital is listening.
Curevo Vaccine, a Seattle-based company, debuted a $60 million Series A on Thursday led by the prominent life sciences VC, aiming to fund a Phase IIb study for its shingles vaccine candidate. The program, known as CRV-101, will be measured against Shingrix as the control and pits the two shots head-to-head.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.